These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37180067)

  • 1. Induced pluripotent stem cells in companion animals: how can we move the field forward?
    Barrachina L; Arshaghi TE; O'Brien A; Ivanovska A; Barry F
    Front Vet Sci; 2023; 10():1176772. PubMed ID: 37180067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.
    Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y
    J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery.
    Singh VK; Kalsan M; Kumar N; Saini A; Chandra R
    Front Cell Dev Biol; 2015; 3():2. PubMed ID: 25699255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equine Induced Pluripotent Stem Cell Culture.
    Falk J; Donadeu FX
    Methods Mol Biol; 2024; 2749():175-184. PubMed ID: 38133784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veterinary applications of induced pluripotent stem cells: regenerative medicine and models for disease?
    Cebrian-Serrano A; Stout T; Dinnyes A
    Vet J; 2013 Oct; 198(1):34-42. PubMed ID: 24129109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of mice derived from induced pluripotent stem cells.
    Boland MJ; Hazen JL; Nazor KL; Rodriguez AR; Martin G; Kupriyanov S; Baldwin KK
    J Vis Exp; 2012 Nov; (69):e4003. PubMed ID: 23222420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and Challenges of Induced Pluripotent Stem Cells in Equine Health.
    Donadeu FX; Esteves CL
    Front Vet Sci; 2015; 2():59. PubMed ID: 26664986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.
    Sundaravadivelu PK; Raina K; Thool M; Ray A; Joshi JM; Kaveeshwar V; Sudhagar S; Lenka N; Thummer RP
    Adv Exp Med Biol; 2022; 1376():151-180. PubMed ID: 34611861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells.
    Chen YS; Pelekanos RA; Ellis RL; Horne R; Wolvetang EJ; Fisk NM
    Stem Cells Transl Med; 2012 Feb; 1(2):83-95. PubMed ID: 23197756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
    Omole AE; Fakoya AOJ
    PeerJ; 2018; 6():e4370. PubMed ID: 29770269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pluripotent stem cell derivation and differentiation toward cardiac muscle: novel techniques and advances in patent literature.
    Quattrocelli M; Thorrez L; Sampaolesi M
    Recent Pat Drug Deliv Formul; 2013 Apr; 7(1):18-28. PubMed ID: 22974171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How far are induced pluripotent stem cells from the clinic?
    Li M; Chen M; Han W; Fu X
    Ageing Res Rev; 2010 Jul; 9(3):257-64. PubMed ID: 20362696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming stem cells in regenerative medicine.
    Mao J; Saiding Q; Qian S; Liu Z; Zhao B; Zhao Q; Lu B; Mao X; Zhang L; Zhang Y; Sun X; Cui W
    Smart Med; 2022 Dec; 1(1):e20220005. PubMed ID: 39188749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MSCs vs. iPSCs: Potential in therapeutic applications.
    Thanaskody K; Jusop AS; Tye GJ; Wan Kamarul Zaman WS; Dass SA; Nordin F
    Front Cell Dev Biol; 2022; 10():1005926. PubMed ID: 36407112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.
    Menon S; Shailendra S; Renda A; Longaker M; Quarto N
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.
    Cerneckis J; Cai H; Shi Y
    Signal Transduct Target Ther; 2024 Apr; 9(1):112. PubMed ID: 38670977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate?
    Boué S; Paramonov I; Barrero MJ; Izpisúa Belmonte JC
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positioning canine induced pluripotent stem cells (iPSCs) in the reprogramming landscape of naïve or primed state in comparison to mouse and human iPSCs.
    Menon DV; Bhaskar S; Sheshadri P; Joshi CG; Patel D; Kumar A
    Life Sci; 2021 Jan; 264():118701. PubMed ID: 33130086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.
    Kramer AS; Harvey AR; Plant GW; Hodgetts SI
    Cell Transplant; 2013; 22(4):571-617. PubMed ID: 22944020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.